Richard Haynes

DM, MRCP

Associate Professor

MRC Project Leader Track
MSc in Global Health Science module 8 lead: Clinical Trials and Meta-Analysis

Richard Haynes did his pre-clinical medical studies in Cambridge before moving to Oxford for his clinical studies and qualified in 2000. He came to CTSU for a period of “out of programme” research in 2006 to work on the HPS2-THRIVE trial with Prof Jane Armitage. He completed his training in renal medicine in 2011 and was appointed as an honorary consultant at the Oxford Kidney Unit. Shortly after that he was appointed to the MRC Programme Leader track and he now works on randomized trials and epidemiology (particularly in renal medicine and cardiovascular disease) at CTSU.

Recent publications

Assessement of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials.
Journal article

Offer A. et al, (2019), JAMA Netw Open, 2
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.
Journal article

Herrington WG. et al, (2019), Ann Intern Med, 170
Feasibility of Telemonitoring Blood Pressure in Patients With Kidney Disease (Oxford Heart and Renal Protection Study-1): Observational Study.
Journal article

Warner BE. et al, (2018), JMIR Cardio, 2
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Journal article

ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1540 - 1550
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
Journal article

ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1529 - 1539

More publications